◆ 会议时间：2025年5月13-16日
◆ 会议地点：加拿大 蒙特利尔
◆ 会议简介：
2025年国际药物经济学与结果研究学会(ISPOR)国际会议/北美年会将于2025年5月13-16日在加拿大蒙特利尔举行。
国际药物经济学与结果研究学会(ISPOR)成立于1995年，是全球领先的致力于药物经济学与结果研究的非营利性国际科学与教育组织，ISPOR目前在全球120多个国家拥有超过10000名成员，此外ISPOR所属分会成员也超过10000人，会员来自于制药、医疗器械、诊断、学术或科研单位、政府机构、临床、医疗管理等行业部门。ISPOR的宗旨是促进药物经济学（卫生经济学）以及健康结果研究的发展，评估卫生医疗干预手段在临床、经济等领域宣的成本效果，为政策制定者提供有科学价值的参考信息。
ISPOR每年召开三次科学会议，包括北美国际年会、欧洲年会和拉丁美洲/亚太年会，ISPOR科学会议是探讨和传播有关卫生经济学和结果研究科学信息的重要平台，每年都有来自120多个国家和地区的12000余名专业人士出席ISPOR大会。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。
ISPOR 2025 - Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Date: May 13-16, 2025
Venue: Montréal, Quebec, Canada
Join global healthcare leaders as they convene at ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR) on May 13 - 16, for discussion and dissemination of the latest trends in healthcare. This must-attend event provides you with dedicated opportunities to network with your peers, HEOR experts, and thought leaders and to discuss with a global audience how we establish, incentivize, and share value sustainable for health systems, patients, and technology developers.
重要日期：
Abstract Information
Important dates for Issue Panel, Workshop, Other Breakout Sessions, & Case Study abstract submissions:
Abstract Submission Opens: October 4, 2024
Abstract Submission Closes: December 12, 2024
Important dates for Research abstract submissions:
Abstract Submission Opens: November 1, 2024
Abstract Submission Closes: January 9, 2025
ISPOR is recognized globally as the leading scientific and educational organization for health economics and outcomes research (HEOR) and its use in healthcare decisions. The Society's scientific conferences provide the ideal venue to share your new research as a podium or poster presentation; interact with attendees during a workshop or other breakout session on your innovative experiences in outcomes research; and/or debate your views on a controversial topic in an issue panel session.
点此查看更多摘要提交相关信息>>>
◆ 参会对象：
政府代表、医院管理者、科室主任、副主任、医生以及从事该领域研究的专家、科研人员、医药企业等。
|
